

## EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	379	cci-779	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/14 10:55
S2	2	("5362718").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/03/08 15:57
S3	479860	formulation	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/08 15:59
S4	268	S1 and S3	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/08 16:01
S5	137854	parenteral	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/08 16:01
S6	138	S4 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/08 16:10
S7	8848	RAPAMYCIN	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/08 16:10

## EAST Search History

S8	213	RAPAMYCIN near ester	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/08 16:11
S9	192	(S1 or S8) and S3 and S5	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/08 16:11
S10	0	PCT/US03/23276	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 11:04
S11	2	("5516770").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/03/12 11:10
S12	2	("5530006").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/03/12 11:16
S13	2	("0649659").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/03/12 11:17
S14	6	ep and "649659"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 11:18

## EAST Search History

S15	2	("5536729").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/03/12 11:19
S17	2	("5559121").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/03/12 14:57
S18	12	"10/626943"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 11:31
S19	2	("5616588").PN.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	OFF	2007/03/14 17:44
S21	379	cci-779	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 15:00
S22	379	S21	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 15:00
S23	207291	parenteral or intravenous or "i.v."	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 15:02

## EAST Search History

S24	213	RAPAMYCIN near ester	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 15:01
S25	213	S24	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 15:02
S26	293	(S22 or S25) and S23	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 15:02
S27	1178498	parenteral or intravenous or "i.v." or injection	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 15:03
S28	349	(S22 or S25) and S27	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/12 15:05
S29	34	temsirolimus	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/14 11:03
S31	12	"10/626943"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/14 11:03

## EAST Search History

S32	11431780	s cremophor	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/14 17:44
S33	11431172	s cremophor.ti.	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/14 17:45
S34	2786912	composition	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/14 17:45
S35	14078	S33 near S34	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2007/03/14 17:46

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAGXP1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 OCT 23 The Derwent World Patents Index suite of databases on STN  
has been enhanced and reloaded  
NEWS 4 OCT 30 CHEMLIST enhanced with new search and display field  
NEWS 5 NOV 03 JAPIO enhanced with IPC 8 features and functionality  
NEWS 6 NOV 10 CA/CAPLUS F-Term thesaurus enhanced  
NEWS 7 NOV 10 STN Express with Discover! free maintenance release Version  
8.01c now available  
NEWS 8 NOV 20 CA/CAPLUS to MARPAT accession number crossover limit increased  
to 50,000  
NEWS 9 DEC 01 CAS REGISTRY updated with new ambiguity codes  
NEWS 10 DEC 11 CAS REGISTRY chemical nomenclature enhanced  
NEWS 11 DEC 14 WPIDS/WPINDEX/WPIX manual codes updated  
NEWS 12 DEC 14 GBFULL and FRFULL enhanced with IPC 8 features and  
functionality  
NEWS 13 DEC 18 CA/CAPLUS pre-1967 chemical substance index entries enhanced  
with preparation role  
NEWS 14 DEC 18 CA/CAPLUS patent kind codes updated  
NEWS 15 DEC 18 MARPAT to CA/CAPLUS accession number crossover limit increased  
to 50,000  
NEWS 16 DEC 18 MEDLINE updated in preparation for 2007 reload  
NEWS 17 DEC 27 CA/CAPLUS enhanced with more pre-1907 records  
NEWS 18 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals  
NEWS 19 JAN 16 CA/CAPLUS Company Name Thesaurus enhanced and reloaded  
NEWS 20 JAN 16 IPC version 2007.01 thesaurus available on STN  
NEWS 21 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data  
NEWS 22 JAN 22 CA/CAPLUS updated with revised CAS roles  
NEWS 23 JAN 22 CA/CAPLUS enhanced with patent applications from India  
NEWS 24 JAN 29 PHAR reloaded with new search and display fields  
NEWS 25 JAN 29 CAS Registry Number crossover limit increased to 300,000 in  
multiple databases  
NEWS 26 FEB 13 CASREACT coverage to be extended  
NEWS 27 Feb 15 PATDPASPC enhanced with Drug Approval numbers  
NEWS 28 Feb 15 RUSSIAPAT enhanced with pre-1994 records  
NEWS 29 Feb 23 KOREAPAT enhanced with IPC 8 features and functionality  
NEWS 30 Feb 26 MEDLINE reloaded with enhancements  
NEWS 31 Feb 26 EMBASE enhanced with Clinical Trial Number field  
NEWS 32 Feb 26 TOXCENTER enhanced with reloaded MEDLINE  
NEWS 33 Feb 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements  
NEWS 34 Feb 26 CAS Registry Number crossover limit increased from 10,000  
to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 15:01:22 ON 08 MAR 2007

=> fil medline, embase, biosis, caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 15:01:48 ON 08 MAR 2007

FILE 'EMBASE' ENTERED AT 15:01:48 ON 08 MAR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:01:48 ON 08 MAR 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:01:48 ON 08 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> e cci-779

E1	6	CCHZ/BI
E2	4621	CCI/BI
E3	0	--> CCI-779/BI
E4	1	CCI01/BI
E5	1	CCI02/BI
E6	12	CCI1/BI
E7	5	CCI103F/BI
E8	11	CCI11/BI
E9	1	CCI111/BI
E10	1	CCI11P15/BI
E11	1	CCI13/BI
E12	15	CCI17/BI

=> s "cci-779"

L1 962 "CCI-779"

=> s "citric acid"

L2 119405 "CITRIC ACID"

=> s tocopherol

L3 99046 TOCOPHEROL

=> s dimethylacetamide

L4 12916 DIMETHYLACETAMIDE

=> s l1 and l2 and l3 and l4

L5 1 L1 AND L2 AND L3 AND L4

=&gt; d l5

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN  
AN 2004:100994 CAPLUS  
DN 140:151982  
TI Parenteral formulations containing a rapamycin hydroxy ester  
IN Rubino, Joseph T.; Siskavich, Victoria; Harrison, Maureen M.; Gandhi, Pooja  
PA Wyeth, John, and Brother Ltd., USA  
SO PCT Int. Appl., 22 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004011000	A1	20040205	WO 2003-US23276	20030725
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2493878	A1	20040205	CA 2003-2493878	20030725
	AU 2003254168	A1	20040216	AU 2003-254168	20030725
	US 2004167152	A1	20040826	US 2003-626943	20030725
	BR 2003013024	A	20050712	BR 2003-13024	20030725
	EP 1553940	A1	20050720	EP 2003-771828	20030725
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1671385	A	20050921	CN 2003-817919	20030725
	JP 2005537285	T	20051208	JP 2004-524806	20030725
	NZ 537829	A	20060929	NZ 2003-537829	20030725
	NO 2005000455	A	20050209	NO 2005-455	20050126
	IN 2005KN00164	A	20060113	IN 2005-KN164	20050210
PRAI	US 2002-399526P	P	20020730		
	WO 2003-US23276	W	20030725		

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=&gt; FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

16.97

17.18

FILE 'STNGUIDE' ENTERED AT 15:05:28 ON 08 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 2, 2007 (20070302/UP).

=&gt; d history

(FILE 'HOME' ENTERED AT 15:01:22 ON 08 MAR 2007)



FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 15:01:48 ON 08 MAR 2007

E CCI-779  
L1 962 S "CCI-779"  
L2 119405 S "CITRIC ACID"  
L3 99046 S TOCOPHEROL  
L4 12916 S DIMETHYLACETAMIDE  
L5 1 S L1 AND L2 AND L3 AND L4

FILE 'STNGUIDE' ENTERED AT 15:05:28 ON 08 MAR 2007

=> file

ENTER A FILE NAME OR (HOME):

ENTER A FILE NAME OR (HOME):

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.78	17.96

FILE 'HOME' ENTERED AT 15:13:21 ON 08 MAR 2007

=> fil medline, embase,biosis,caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	18.17

FILE 'MEDLINE' ENTERED AT 15:13:30 ON 08 MAR 2007

FILE 'EMBASE' ENTERED AT 15:13:30 ON 08 MAR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 15:13:30 ON 08 MAR 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:13:30 ON 08 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d history

(FILE 'HOME' ENTERED AT 15:01:22 ON 08 MAR 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 15:01:48 ON 08 MAR 2007

E CCI-779  
L1 962 S "CCI-779"  
L2 119405 S "CITRIC ACID"  
L3 99046 S TOCOPHEROL  
L4 12916 S DIMETHYLACETAMIDE  
L5 1 S L1 AND L2 AND L3 AND L4

FILE 'STNGUIDE' ENTERED AT 15:05:28 ON 08 MAR 2007

FILE 'HOME' ENTERED AT 15:13:21 ON 08 MAR 2007

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 15:13:30 ON 08 MAR 2007

=> s l1 and l3 and l4

L6 1 L1 AND L3 AND L4

=> s l1 and l3

L7 2 L1 AND L3

=> d l7 1-2

L7 ANSWER 1 OF 2 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN  
 AN 2005204177 EMBASE  
 TI Targeted therapies for prostate cancer.  
 AU Asatiani E.; Gelman E.P.  
 CS Dr. E.P. Gelmann, Georgetown University, Department of Oncology, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington, DC 20007-2197, United States. gelmanne@georgetown.edu  
 SO Expert Opinion on Therapeutic Targets, (2005) Vol. 9, No. 2, pp. 283-298.

Refs: 178

ISSN: 1472-8222 CODEN: EOTTAO

CY United Kingdom

DT Journal; General Review

FS 016 Cancer

028 Urology and Nephrology

029 Clinical Biochemistry

030 Pharmacology

037 Drug Literature Index

038 Adverse Reactions Titles

LA English

SL English

ED Entered STN: 19 May 2005

Last Updated on STN: 19 May 2005

L7 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:100994 CAPLUS

DN 140:151982

TI Parenteral formulations containing a rapamycin hydroxy ester

IN Rubino, Joseph T.; Siskavich, Victoria; Harrison, Maureen M.; Gandhi, Pooja

PA Wyeth, John, and Brother Ltd., USA

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004011000	A1	20040205	WO 2003-US23276	20030725
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2493878	A1	20040205	CA 2003-2493878	20030725
	AU 2003254168	A1	20040216	AU 2003-254168	20030725
	US 2004167152	A1	20040826	US 2003-626943	20030725
	BR 2003013024	A	20050712	BR 2003-13024	20030725
	EP 1553940	A1	20050720	EP 2003-771828	20030725
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	CN 1671385	A	20050921	CN 2003-817919	20030725
	JP 2005537285	T	20051208	JP 2004-524806	20030725
	NZ 537829	A	20060929	NZ 2003-537829	20030725
	NO 2005000455	A	20050209	NO 2005-455	20050126
	IN 2005KN00164	A	20060113	IN 2005-KN164	20050210

PRAI US 2002-399526P P 20020730  
WO 2003-US23276 W 20030725  
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	7.74	25.91

FILE 'STNGUIDE' ENTERED AT 15:14:55 ON 08 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 2, 2007 (20070302/UP).

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.54	26.45

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 15:20:31 ON 08 MAR 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAGXP1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS 7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS 9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS 10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS 11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS 12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS 13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS 14	DEC 18	CA/CAPLUS patent kind codes updated

NEWS 15 DEC 18 MARPAT to CA/Capplus accession number crossover limit increased to 50,000

NEWS 16 DEC 18 MEDLINE updated in preparation for 2007 reload

NEWS 17 DEC 27 CA/Capplus enhanced with more pre-1907 records

NEWS 18 JAN 08 CHEMLIST enhanced with New Zealand Inventory of Chemicals

NEWS 19 JAN 16 CA/Capplus Company Name Thesaurus enhanced and reloaded

NEWS 20 JAN 16 IPC version 2007.01 thesaurus available on STN

NEWS 21 JAN 16 WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data

NEWS 22 JAN 22 CA/Capplus updated with revised CAS roles

NEWS 23 JAN 22 CA/Capplus enhanced with patent applications from India

NEWS 24 JAN 29 PHAR reloaded with new search and display fields

NEWS 25 JAN 29 CAS Registry Number crossover limit increased to 300,000 in multiple databases

NEWS 26 FEB 13 CASREACT coverage to be extended

NEWS 27 Feb 15 PATDPASPC enhanced with Drug Approval numbers

NEWS 28 Feb 15 RUSSIAPAT enhanced with pre-1994 records

NEWS 29 Feb 23 KOREAPAT enhanced with IPC 8 features and functionality

NEWS 30 Feb 26 MEDLINE reloaded with enhancements

NEWS 31 Feb 26 EMBASE enhanced with Clinical Trial Number field

NEWS 32 Feb 26 TOXCENTER enhanced with reloaded MEDLINE

NEWS 33 Feb 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements

NEWS 34 Feb 26 CAS Registry Number crossover limit increased from 10,000 to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

NEWS LOGIN Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:28:13 ON 12 MAR 2007

=> file medline embase biosis caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'MEDLINE' ENTERED AT 11:28:43 ON 12 MAR 2007

FILE 'EMBASE' ENTERED AT 11:28:43 ON 12 MAR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:28:43 ON 12 MAR 2007

Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:28:43 ON 12 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s composition  
L1 2912414 COMPOSITION

=> s rapamycin  
L2 27270 RAPAMYCIN

=> "cci-779" or "cci 779"  
L3 967 "CCI-779" OR "CCI 779"

=> s cci (w) 779  
L4 967 CCI (W) 779

=> s composition.ti.  
L5 338 COMPOSITION.TI.

=> s rapamycin.ti.  
L6 0 RAPAMYCIN.TI.

=> s injection  
L7 1635714 INJECTION

=> s "i.v." or "iv" or intravenous  
L8 2199655 "I.V." OR "IV" OR INTRAVENOUS

=> s parental  
L9 185951 PARENTAL

=> s formulation  
L10 405720 FORMULATION

=> s (l1 or l10) and (l3 or l2) and (l7 or l8 or l9)  
L11 194 (L1 OR L10) AND (L3 OR L2) AND (L7 OR L8 OR L9)

=> s ethanol  
L12 502458 ETHANOL

=> s "polyethylene glycol" or PEG  
L13 201037 "POLYETHYLENE GLYCOL" OR PEG

=> s l11 and l12 and l13  
L14 4 L11 AND L12 AND L13

=> d l14 1-4

L14 ANSWER 1 OF 4 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

AN 2004081205 EMBASE

TI Solubilizing Excipients in Oral and Injectable Formulations.

AU Strickley R.G.

CS R.G. Strickley, Formulation and Process Development, Gilead Sciences Inc., Foster City, CA 94404, United States. rstrickley@gilead.com

SO Pharmaceutical Research, (2004) Vol. 21, No. 2, pp. 201-230. .

Refs: 90

ISSN: 0724-8741 CODEN: PHREEB

CY United States

DT Journal; General Review

FS 030 Pharmacology  
037 Drug Literature Index  
039 Pharmacy

LA English

SL English

ED Entered STN: 18 Mar 2004

Last Updated on STN: 18 Mar 2004

L14 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:251588 CAPLUS

DN 144:474854

TI Medical compositions containing rapamycin in combination with other antitumor drugs for the treatment of cancer

IN Chang, Junbiao; Xie, Weilin; Cheng, Senxiang; Zhao, Kang

PA Xinxiang Medical College, Peop. Rep. China

SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 13 pp.

CODEN: CNXXEV

DT Patent

LA Chinese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	CN 1739509	A	20060301	CN 2005-10017980	20050908
PRAI	CN 2005-10017980		20050908		

L14 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:902155 CAPLUS

DN 141:384286

TI Novel encochleation methods, cochleates and methods of use

IN Mannino, Raphael J.; Gould-Fogerite, Susan; Krause-Elsmore, Sara L.; Delmarre, David; Lu, Ruying

PA Biodelivery Sciences International, Inc., USA; University of Medicine and Dentistry of New Jersey

SO PCT Int. Appl., 195 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004091578	A2	20041028	WO 2004-US11026	20040409
	WO 2004091578	A8	20050127		
	WO 2004091578	A3	20050331		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW:				
	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2005013854	A1	20050120	US 2004-822230	20040409
	EP 1624858	A2	20060215	EP 2004-759375	20040409
	R:				
	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
PRAI	US 2003-461483P	P	20030409		
	US 2003-463076P	P	20030415		
	US 2003-499247P	P	20030828		
	US 2003-502557P	P	20030911		
	US 2003-532755P	P	20031224		
	US 2004-537252P	P	20040115		
	US 2004-556192P	P	20040324		
	WO 2004-US11026	W	20040409		

L14 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:100994 CAPLUS

DN 140:151982  
 TI Parenteral formulations containing a rapamycin hydroxy  
 ester  
 IN Rubino, Joseph T.; Siskavich, Victoria; Harrison, Maureen M.; Gandhi,  
 Pooja  
 PA Wyeth, John, and Brother Ltd., USA  
 SO PCT Int. Appl., 22 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004011000	A1	20040205	WO 2003-US23276	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: KH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2493878	A1	20040205	CA 2003-2493878	20030725
AU 2003254168	A1	20040216	AU 2003-254168	20030725
US 2004167152	A1	20040826	US 2003-626943	20030725
BR 2003013024	A	20050712	BR 2003-13024	20030725
EP 1553940	A1	20050720	EP 2003-771828	20030725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1671385	A	20050921	CN 2003-817919	20030725
JP 2005537285	T	20051208	JP 2004-524806	20030725
NZ 537829	A	20060929	NZ 2003-537829	20030725
NO 2005000455	A	20050209	NO 2005-455	20050126
IN 2005KN00164	A	20060113	IN 2005-KN164	20050210
PRAI US 2002-399526P	P	20020730		
WO 2003-US23276	W	20030725		

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

76.02

76.23

FILE 'STNGUIDE' ENTERED AT 11:46:36 ON 12 MAR 2007

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE

AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Mar 9, 2007 (20070309/UP).

=> file medline embase biosis caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.24

76.47

FILE 'MEDLINE' ENTERED AT 11:49:00 ON 12 MAR 2007

FILE 'EMBASE' ENTERED AT 11:49:00 ON 12 MAR 2007

Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:49:00 ON 12 MAR 2007  
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:49:00 ON 12 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> d hist

(FILE 'HOME' ENTERED AT 11:28:13 ON 12 MAR 2007)

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 11:28:43 ON 12 MAR 2007

L1 2912414 S COMPOSITION  
L2 27270 S RAPAMYCIN  
L3 967 "CCI-779" OR "CCI 779"  
L4 967 S CCI (W) 779  
L5 338 S COMPOSITION.TI.  
L6 0 S RAPAMYCIN.TI.  
L7 1635714 S INJECTION  
L8 2199655 S "I.V." OR "IV" OR INTRAVENOUS  
L9 185951 S PARENTAL  
L10 405720 S FORMULATION  
L11 194 S (L1 OR L10) AND (L3 OR L2) AND (L7 OR L8 OR L9)  
L12 502458 S ETHANOL  
L13 201037 S "POLYETHYLENE GLYCOL" OR PEG  
L14 4 S L11 AND L12 AND L13

FILE 'STNGUIDE' ENTERED AT 11:46:36 ON 12 MAR 2007

FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS' ENTERED AT 11:49:00 ON 12 MAR 2007

=> s solubilization

L15 69022 SOLUBILIZATION

=> s l11 and l15

L16 0 L11 AND L15

=> s l3 and l15

L17 0 L3 AND L15

=> s l11 and excipients

L18 2 L11 AND EXCIPIENTS

=> d l18 1-2

L18 ANSWER 1 OF 2 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN  
AN 2004436372 EMBASE  
TI The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs.  
AU Kipp J.E.  
CS kippj@baxter.com  
SO International Journal of Pharmaceutics, (13 Oct 2004) Vol. 284, No. 1-2, pp. 109-122. .  
Refs: 76  
ISSN: 0378-5173 CODEN: IJPHDE  
PUI S 0378-5173(04)00458-2  
CY Netherlands  
DT Journal; General Review  
FS 037 Drug Literature Index



039 Pharmacy  
LA English  
SL English  
ED Entered STN: 28 Oct 2004  
Last Updated on STN: 28 Oct 2004

L18 ANSWER 2 OF 2 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN  
AN 2004081205 EMBASE  
TI Solubilizing Excipients in Oral and Injectable Formulations.  
AU Strickley R.G.  
CS R.G. Strickley, Formulation and Process Development, Gilead Sciences Inc., Foster City, CA 94404, United States. rstrickley@gilead.com  
SO Pharmaceutical Research, (2004) Vol. 21, No. 2, pp. 201-230. .  
Refs: 90  
ISSN: 0724-8741 CODEN: PHREEB  
CY United States  
DT Journal; General Review  
FS 030 Pharmacology  
037 Drug Literature Index  
039 Pharmacy  
LA English  
SL English  
ED Entered STN: 18 Mar 2004  
Last Updated on STN: 18 Mar 2004

=> FIL STNGUIDE  
COST IN U.S. DOLLARS  
FULL ESTIMATED COST

SINCE FILE	TOTAL
ENTRY	SESSION
13.88	90.35

FILE 'STNGUIDE' ENTERED AT 11:51:44 ON 12 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Mar 9, 2007 (20070309/UP).

=> save  
ENTER L#, L# RANGE, ALL, OR (END):all  
ENTER NAME OR (END):cci779  
CCI779 IS NOT A VALID SAVED NAME  
Enter the name you wish to use for the saved query,  
answer set, or L-number list. The name must:  
1. Begin with a letter,  
2. Have 1-12 characters,  
3. Contain only letters (A-Z) and numbers (0-9),  
4. End with /Q for a query (search profile,  
structure, or screen set), /A for an answer  
set, or /L for an L-number list.  
5. Not already be in use as a saved name,  
6. Not be END, SAV, SAVE, SAVED  
7. Not have the form of an L-number (Lnnn).  
ENTER NAME OR (END):cci779/q  
'CCI779/Q' IS NOT ALLOWED WITH ALL  
The saved name of an L# list must end with '/L'.

=> save  
ENTER L#, L# RANGE, ALL, OR (END):all  
ENTER NAME OR (END):cci779/l

L# LIST L1-L18 HAS BEEN SAVED AS 'CCI779/L'

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE

ENTRY

TOTAL

SESSION

FULL ESTIMATED COST

0.24

90.59

STN INTERNATIONAL LOGOFF AT 11:54:17 ON 12 MAR 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAGXP1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	4	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	5	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	6	NOV 10	CA/CAPLUS F-Term thesaurus enhanced
NEWS	7	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	8	NOV 20	CA/CAPLUS to MARPAT accession number crossover limit increased to 50,000
NEWS	9	DEC 01	CAS REGISTRY updated with new ambiguity codes
NEWS	10	DEC 11	CAS REGISTRY chemical nomenclature enhanced
NEWS	11	DEC 14	WPIDS/WPINDEX/WPIX manual codes updated
NEWS	12	DEC 14	GBFULL and FRFULL enhanced with IPC 8 features and functionality
NEWS	13	DEC 18	CA/CAPLUS pre-1967 chemical substance index entries enhanced with preparation role
NEWS	14	DEC 18	CA/CAPLUS patent kind codes updated
NEWS	15	DEC 18	MARPAT to CA/CAPLUS accession number crossover limit increased to 50,000
NEWS	16	DEC 18	MEDLINE updated in preparation for 2007 reload
NEWS	17	DEC 27	CA/CAPLUS enhanced with more pre-1907 records
NEWS	18	JAN 08	CHEMLIST enhanced with New Zealand Inventory of Chemicals
NEWS	19	JAN 16	CA/CAPLUS Company Name Thesaurus enhanced and reloaded
NEWS	20	JAN 16	IPC version 2007.01 thesaurus available on STN
NEWS	21	JAN 16	WPIDS/WPINDEX/WPIX enhanced with IPC 8 reclassification data
NEWS	22	JAN 22	CA/CAPLUS updated with revised CAS roles
NEWS	23	JAN 22	CA/CAPLUS enhanced with patent applications from India
NEWS	24	JAN 29	PHAR reloaded with new search and display fields
NEWS	25	JAN 29	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	26	FEB 13	CASREACT coverage to be extended
NEWS	27	FEB 15	PATDPASPC enhanced with Drug Approval numbers
NEWS	28	FEB 15	RUSSIAPAT enhanced with pre-1994 records

NEWS 29 Feb 23 KOREAPAT enhanced with IPC 8 features and functionality  
NEWS 30 Feb 26 MEDLINE reloaded with enhancements  
NEWS 31 Feb 26 EMBASE enhanced with Clinical Trial Number field  
NEWS 32 Feb 26 TOXCENTER enhanced with reloaded MEDLINE  
NEWS 33 Feb 26 IFICDB/IFIPAT/IFIUDB reloaded with enhancements  
NEWS 34 Feb 26 CAS Registry Number crossover limit increased from 10,000  
to 300,000 in multiple databases

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items  
NEWS IPC8 For general information regarding STN implementation of IPC 8  
NEWS X25 X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:50:52 ON 14 MAR 2007

=> file medline embase biosis caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.05	1.05

FILE 'MEDLINE' ENTERED AT 11:53:48 ON 14 MAR 2007

FILE 'EMBASE' ENTERED AT 11:53:48 ON 14 MAR 2007  
Copyright (c) 2007 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 11:53:48 ON 14 MAR 2007  
Copyright (c) 2007 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 11:53:48 ON 14 MAR 2007  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s powell/AU  
L1 5 POWELL/AU

=> D L1 IBIB ABS 1-5

L1 ANSWER 1 OF 5 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights  
reserved on STN

ACCESSION NUMBER: 2005153001 EMBASE  
TITLE: Erratum: Vitamin D, shedding light on the development of  
disease in peripheral arteries (Arteriosclerosis,  
Thrombosis, and Vascular Biology (January 2005) 25  
(39-46)).  
AUTHOR: Norma; Powell  
SOURCE: Arteriosclerosis, Thrombosis, and Vascular Biology, (2005)  
Vol. 25, No. 4, pp. 875. .

ISSN: 1079-5642 CODEN: ATVBFA  
COUNTRY: United States  
DOCUMENT TYPE: Journal; Errata  
FILE SEGMENT: 018 Cardiovascular Diseases and Cardiovascular Surgery  
LANGUAGE: English  
ENTRY DATE: Entered STN: 5 May 2005  
Last Updated on STN: 5 May 2005  
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L1 ANSWER 2 OF 5 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN  
ACCESSION NUMBER: 1999323379 EMBASE  
TITLE: Evidence against prophylactic repair of small, asymptomatic abdominal aortic aneurysms.  
AUTHOR: Powell  
SOURCE: European Heart Journal, (1999) Vol. 20, No. 19, pp. 1365-1369. .  
Refs: 4  
ISSN: 0195-668X CODEN: EHJODF  
COUNTRY: United Kingdom  
DOCUMENT TYPE: Journal; Editorial  
FILE SEGMENT: 009 Surgery  
018 Cardiovascular Diseases and Cardiovascular Surgery  
036 Health Policy, Economics and Management  
LANGUAGE: English  
ENTRY DATE: Entered STN: 30 Sep 1999  
Last Updated on STN: 30 Sep 1999  
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L1 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN  
ACCESSION NUMBER: 77014939 EMBASE  
DOCUMENT NUMBER: 1977014939  
TITLE: A clinical trial with a live bivalent attenuated intranasal influenza A/B vaccine (Alice/R 75 vaccine).  
AUTHOR: Spencer M.J.; Cherry J.D.; Powell; Sumaya C.V.  
CORPORATE SOURCE: Dept. Ped., UCLA, Los Angeles, Calif., United States  
SOURCE: Clinical Research, (1976) Vol. 24, No. 2, pp. 115A. .  
CODEN: CLREAS  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L1 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
ACCESSION NUMBER: 2003:524761 BIOSIS  
DOCUMENT NUMBER: PREV200300526505  
TITLE: A simulation model of population growth of hard clams (Mercenaria mercenaria). II. Effects of fishing.  
AUTHOR(S): Kraeuter [Reprint Author]; Powell; Hofmann; Klinck; Grizzle; Bricelj; Buckner  
CORPORATE SOURCE: Haskin Shellfish Research Laboratory, Rutgers University, 6959 Miller Avenue, Port Norris, NJ, 08349, USA  
SOURCE: Journal of Shellfish Research, (June 2003) Vol. 22, No. 1, pp. 338. print.  
Meeting Info.: 95th Annual Meeting of the National Shellfisheries Association. New Orleans, LO, USA. April 13-17, 2003.  
CODEN: JSHRDA. ISSN: 0730-8000.  
DOCUMENT TYPE: Conference; (Meeting)  
Conference; Abstract; (Meeting Abstract)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 12 Nov 2003  
Last Updated on STN: 12 Nov 2003

L1 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN  
ACCESSION NUMBER: 1911:6276 CAPLUS  
DOCUMENT NUMBER: 5:6276  
ORIGINAL REFERENCE NO.: 5:1139f-i  
TITLE: Sterilization of Water  
AUTHOR(S): Walden; Powell  
SOURCE: Am. Water Works Assn. (1910) 128  
DOCUMENT TYPE: Journal  
LANGUAGE: Unavailable

AB Results of expts. which the Baltimore Co. Water & Elec. Co. have been making with slow sand and mechanical filters, with and without the aid of ozone and bleaching powder as sterilization agents. The ozone sterilization apparatus makes considerable reduction in the number of bacteria. Since the construction of rapid filters at the Company's filtration plant at Avalon, Md., in 1908, bleaching powder has been used for sterilizing the water in connection with filtration at this plant. The chemical has been used continuously, not because of the failure of filtration alone but to lessen the cost of operation and at the same time to deliver water which was practically steril. Results show that the effluent from both slow sand and mechanical filters can be made practically steril, with a total elimination of *B. coli*, reducing the color from 5-15%; that it causes a reduction in the amount of alum and an increase in the length of runs between washings, and at the same time a reduction in the amount of wash water.  $\text{Ca}(\text{OCl})_2$  is more efficient when used with Al sulfate than when used alone. The high turbidity in the raw water reduces the bacterial efficiency of the bleaching powder. The bleaching powder, even when used in large quantities, causes but a slight reduction in organic matter. The bleaching powder was added directly to the reservoir water before filtration.

=> LOGOFF HOLD

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	19.85	20.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

SESSION WILL BE HELD FOR 120 MINUTES  
STN INTERNATIONAL SESSION SUSPENDED AT 11:56:32 ON 14 MAR 2007

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAGXP1614

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'MEDLINE, EMBASE, BIOSIS, CAPLUS'  
AT 13:05:17 ON 14 MAR 2007  
FILE 'MEDLINE' ENTERED AT 13:05:17 ON 14 MAR 2007  
FILE 'EMBASE' ENTERED AT 13:05:17 ON 14 MAR 2007  
Copyright (c) 2007 Elsevier B.V. All rights reserved.  
FILE 'BIOSIS' ENTERED AT 13:05:17 ON 14 MAR 2007  
Copyright (c) 2007 The Thomson Corporation  
FILE 'CAPLUS' ENTERED AT 13:05:17 ON 14 MAR 2007

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	19.85	20.90
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-0.78	-0.78

=> s powell  
L2 2494 POWELL

=> parenteral  
L3 153016 PARENTERAL

=> s l2 and l3  
L4 3 L2 AND L3

=> d ibib abs 1-3

L4 ANSWER 1 OF 3 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004505031 EMBASE  
TITLE: ISCOMATRIX® adjuvant for antigen delivery.  
AUTHOR: Pearse M.J.; Drane D.  
CORPORATE SOURCE: martin.pearse@csl.com.au  
SOURCE: Advanced Drug Delivery Reviews, (10 Jan 2005) Vol. 57, No. 3 SPEC. ISS., pp. 465-474. .  
Refs: 32  
ISSN: 0169-409X CODEN: ADDREP  
PUBLISHER IDENT.: S 0169-409X(04)00213-3  
COUNTRY: Netherlands  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 004 Microbiology  
026 Immunology, Serology and Transplantation  
037 Drug Literature Index  
038 Adverse Reactions Titles  
039 Pharmacy  
LANGUAGE: English  
SUMMARY LANGUAGE: English  
ENTRY DATE: Entered STN: 17 Dec 2004  
Last Updated on STN: 17 Dec 2004

AB The immunostimulating complex, referred to as 'iscom', was first described by Morein et al. in 1984 as a novel structure for antigenic presentation of membrane proteins from enveloped viruses with potent immunomodulatory capability [B. Morein, B. Sundquist, S. Hoglund, K. Dalsgaard, A. Osterhaus. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 308 (1984) 457-460.]. Since this discovery, many vaccines have been tested in animal models showing the induction of both humoral and cellular immune responses [A. Sjolander, J.C. Cox, L.G. Barr. ISCOMs: an adjuvant with multiple functions, J. Leukoc. Biol. 64 (1998) 713-723.]. The ISCOMATRIX® adjuvant is essentially the same structure as the iscom but without the incorporated antigen [G.F. Rimmelzwaan, A.D.M.E. Osterhaus. A novel generation of viral vaccines based on ISCOM matrix, in: M.F. Powell, M.J. Newman (Eds.). Vaccine Design, the Subunit and Adjuvant Approach, Plenum, New York, 1995 pp. 543-558.]. Antigens can be formulated with the ISCOMATRIX® adjuvant to produce ISCOMATRIX® vaccines that can provide the same antigen presentation and immunomodulatory properties as the iscom but with much broader application as they are not limited to hydrophobic membrane proteins. Various ISCOMATRIX® vaccines have been tested in animal models and more

recently in human clinical trials [G. Kersten, D. Drane, M. Pearse, W. Jiskoot, A. Coulter. Liposomes and ISCOMs, in: Novel Vaccination Strategies, 2003 pp. 173-196.]. These studies have shown that the ISCOMATRIX® adjuvant is safe and induces both humoral and cellular immune responses. The ability of the ISCOMATRIX® adjuvant to induce these broad immune responses is due to the combination of antigen presentation by both MHC class I and class II pathways, and the powerful immunomodulatory capability of the saponin. Additionally, the ISCOMATRIX® adjuvant is simple to manufacture and can be combined with a wide range of antigens making it suitable for the development of novel human vaccines. .COPYRGHT. 2004 Elsevier B.V. All rights reserved.

L4 ANSWER 2 OF 3 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN  
ACCESSION NUMBER: 87208624 EMBASE  
DOCUMENT NUMBER: 1987208624  
TITLE: Epidemiology, diagnosis, and management of Malassezia furfur systemic infection.  
AUTHOR: Marcon M.J.; Powell D.A.  
CORPORATE SOURCE: Section of Clinical Microbiology, Department of Laboratory Medicine, Children's Hospital, Columbus, OH 43205, United States  
SOURCE: Diagnostic Microbiology and Infectious Disease, (1987) Vol. 7, No. 3, pp. 161-175. .  
ISSN: 0732-8893 CODEN: DMIDDZ  
COUNTRY: United States  
DOCUMENT TYPE: Journal  
FILE SEGMENT: 004 Microbiology  
007 Pediatrics and Pediatric Surgery  
017 Public Health, Social Medicine and Epidemiology  
LANGUAGE: English

AB Most clinical microbiologists and physicians identify Malassezia furfur as the 'spaghetti and meatball' appearing yeast that causes tinea versicolor, a chronic, scaling, skin disease. However, recent data from several institutions clearly implicate this normal skin flora organism as a cause of intravascular catheter-related sepsis in patients, particularly infants, receiving parenteral fat emulsions through deep-vein catheters for caloric supplementation (Powell et al., 1984; Redline et al., 1985; Long and Keyserling, 1985). The fat emulsions contain medium and long-chained fatty acids essential for growth of M. furfur, and presumably support its attachment and replication on the surface of intravascular catheters. Once attached to the catheter, the fate of the organism and the mechanism of pathogenesis are still unclear. This article will review data on the microbiology and illness related to M. furfur systemic infection, particularly catheter-related sepsis.

L4 ANSWER 3 OF 3 BIOSIS COPYRIGHT (c) 2007 The Thomson Corporation on STN  
ACCESSION NUMBER: 2006:137824 BIOSIS  
DOCUMENT NUMBER: PREV200600133837  
TITLE: A novel allogeneic transplant conditioning regimen designed for tolerance induction in patients with severe sickle cell disease.  
AUTHOR(S): Kang, Elizabeth M. [Reprint Author]; Hsieh, Matthew; Powell, Jonathan D.; Link, Beth; Donohue, Theresa; Kato, Gregory; Machado, Robert; Gladwin, Mark; Rodgers, Griffin; Tisdale, John F.  
CORPORATE SOURCE: NIAID, LHD, NIH, Bethesda, MD 20892 USA  
SOURCE: Blood, (NOV 16 2005) Vol. 106, No. 11, Part 2, pp. 443B. Meeting Info.: 47th Annual Meeting of the American-Society-of-Hematology. Atlanta, GA, USA. December 10 -13, 2005. Amer Soc Hematol.  
CODEN: BLOOAW. ISSN: 0006-4971.  
DOCUMENT TYPE: Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LANGUAGE: English

ENTRY DATE: Entered STN: 22 Feb 2006

Last Updated on STN: 22 Feb 2006

AB Allogeneic transplantation of hematopoietic stem cells remains the only curative approach for patients with sickle cell disease (SCD), yet procedural toxicities and graft-versus-host disease limit this approach to children. We chose a low-dose radiation approach utilizing rapamycin based upon its unique ability to promote T cell tolerance even when T cells are stimulated in the presence of costimulation (Powell, et al, J Immunol. 1999). We confirmed this approach in vivo in a murine bone marrow transplantation model comparing a short course of conventional immunosuppression with cyclosporine to that with rapamycin, with long-term, high-level chimerism attained only in mice treated with rapamycin (Powell et al., manuscript submitted). We have now begun accrual to an IRB approved clinical trial testing this approach in adults with SCD and herein report the results in our first two subjects. Protocol entry criteria include those previously reported (Walters, et al, NEJM, 1996) with the addition of pulmonary hypertension defined as a tricuspid-regurgitant jet velocity (TRV) > 2.5 m/s (Gladwin et al, NEJM, 2004). Additionally, patients must have failed a 6-month course of hydroxyurea. The conditioning regimen consists of a single radiation dose of 300cGy, alemtuzumab (1 mg/kg total), and oral rapamycin targeting trough levels between 10-20 ng/ml. The graft consists of unmanipulated mobilized peripheral blood progenitors obtained from an HLA-matched sibling. The first patient is a 24-year-old female referred due to recurrent transient ischemic attacks and strokes despite chronic exchange transfusions. Her initial evaluation was notable for evidence of significant hemolysis with a total bilirubin of 9.8 mg/dl, an LDH 1,172 units/L (range 113-226), an absolute reticulocyte count of 318,000/uL and an undetectable haptoglobin. Cardiac doppler-echocardiogram, revealed a TRV of 3.7 m/s, consistent with severe pulmonary hypertension. The conditioning was well tolerated and the patient did not require parenteral antibiotics or nutritional support. Assessment of donor chimerism, measured by microsatellite PCR and hemoglobin electrophoresis, revealed an early peak of myeloid chimerism which has stabilized at approximately 60%, with lower levels of lymphoid chimerism at approximately 5-10% now more than 300 days post-transplant. Hemoglobin levels stabilized at 11-12 g/dL, without detectable sickle hemoglobin, now allowing for therapeutic phlebotomy. Remarkably, the LDH and TRV fell concurrently toward the normal range. Patient 2 is a 26 year old male with frequent crises requiring hospitalization twice monthly. At one month post-transplant, myeloid chimerism is 97%, with lymphoid chimerism currently immeasurable due to lymphopenia, and similar to that seen in patient 1 at the same time point. Patient 2 also required neither parenteral antibiotics nor nutritional support. Finally, neither patient to date has developed any symptoms or signs of either acute or chronic GVHD. Thus with two patients accrued to date, we have demonstrated the ability of allogeneic HSC transplantation to achieve mixed hematopoietic chimerism without the development of GVHD and for the first time, established the reversibility of the associated pulmonary hypertension.

=&gt; s "compendium of excipients for parenteral formulations"

L5 2 "COMPENDIUM OF EXCIPIENTS FOR PARENTERAL FORMULATIONS"

=&gt; d ibib abs 1-2

L5 ANSWER 1 OF 2 MEDLINE on STN

ACCESSION NUMBER: 1999062504 MEDLINE

DOCUMENT NUMBER: PubMed ID: 9846074

TITLE: Compendium of excipients  
for parenteral formulations.



AUTHOR: Powell M F; Nguyen T; Baloian L  
CORPORATE SOURCE: Genentech, Inc., South San Francisco, California, USA.  
SOURCE: PDA journal of pharmaceutical science and technology / PDA,  
(1998 Sep-Oct) Vol. 52, No. 5, pp. 238-311.  
Journal code: 9439538. ISSN: 1079-7440.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Priority Journals  
ENTRY MONTH: 199901  
ENTRY DATE: Entered STN: 15 Jan 1999  
Last Updated on STN: 15 Jan 1999  
Entered Medline: 6 Jan 1999

L5 ANSWER 2 OF 2 EMBASE COPYRIGHT (c) 2007 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 1998409059 EMBASE  
TITLE: Compendium of excipients  
for parenteral formulations.  
AUTHOR: Powell M.F.; Nguyen T.; Baloian L.  
CORPORATE SOURCE: T. Nguyen, Pharmaceut. Research and Development, Genentech,  
Inc., South San Francisco, CA, United States  
SOURCE: PDA Journal of Pharmaceutical Science and Technology,  
(1998) Vol. 52, No. 5, pp. 238-239. .  
ISSN: 1079-7440 CODEN: JPHTEU  
COUNTRY: United States  
DOCUMENT TYPE: Journal; General Review  
FILE SEGMENT: 039 Pharmacy  
LANGUAGE: English  
ENTRY DATE: Entered STN: 4 Feb 1999  
Last Updated on STN: 4 Feb 1999  
DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

=> d 1

L5 ANSWER 1 OF 2 MEDLINE on STN  
AN 1999062504 MEDLINE  
DN PubMed ID: 9846074  
TI Compendium of excipients for  
parenteral formulations.  
AU Powell M F; Nguyen T; Baloian L  
CS Genentech, Inc., South San Francisco, California, USA.  
SO PDA journal of pharmaceutical science and technology / PDA, (1998 Sep-Oct)  
Vol. 52, No. 5, pp. 238-311.  
Journal code: 9439538. ISSN: 1079-7440.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199901  
ED Entered STN: 15 Jan 1999  
Last Updated on STN: 15 Jan 1999  
Entered Medline: 6 Jan 1999

=> d 1 all

L5 ANSWER 1 OF 2 MEDLINE on STN  
AN 1999062504 MEDLINE  
DN PubMed ID: 9846074  
TI Compendium of excipients for  
parenteral formulations.

AU Powell M F; Nguyen T; Baloian L  
CS Genentech, Inc., South San Francisco, California, USA.  
SO PDA journal of pharmaceutical science and technology / PDA, (1998 Sep-Oct)  
Vol. 52, No. 5, pp. 238-311.  
Journal code: 9439538. ISSN: 1079-7440.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199901  
ED Entered STN: 15 Jan 1999  
Last Updated on STN: 15 Jan 1999  
Entered Medline: 6 Jan 1999  
CT Databases, Factual  
\*Excipients  
Infusions, Parenteral  
Pharmaceutical Solutions  
CN 0 (Excipients); 0 (Pharmaceutical Solutions)

=> s "solubility principles and practices for parenteral"  
L6 2 "SOLUBILITY PRINCIPLES AND PRACTICES FOR PARENTERAL"

=> d all

L6 ANSWER 1 OF 2 MEDLINE on STN  
AN 97128545 MEDLINE  
DN PubMed ID: 8973121  
TI Solubility principles and practices  
for parenteral drug dosage form development.  
AU Sweetana S; Akers M J  
CS Pharmaceutical Sciences, Lilly Research Laboratories, Indianapolis,  
Indiana, USA.  
SO PDA journal of pharmaceutical science and technology / PDA, (1996 Sep-Oct)  
Vol. 50, No. 5, pp. 330-42.  
Journal code: 9439538. ISSN: 1079-7440.  
CY United States  
DT Journal; Article; (JOURNAL ARTICLE)  
LA English  
FS Priority Journals  
EM 199701  
ED Entered STN: 28 Jan 1997  
Last Updated on STN: 28 Jan 1997  
Entered Medline: 16 Jan 1997  
AB Solubilization of poorly water soluble or water insoluble drugs for use in  
intravenously administered dosage forms is a very formidable task for the  
parenteral formulation scientist. We have briefly reviewed pertinent  
literature for parenteral drug solubilization and provided tabular  
information to assist parenteral formulation scientists in tackling and  
solving their solubility problems. However, until we can better  
understand and predict solubility behavior in interactive solvent systems,  
the why's and how's for parenteral drug solubilization using acceptable  
(safe and regulatory compliant) approaches will largely remain an  
empirical effort, leaving great opportunities for scientists to get more  
involved in this field.  
CT \*Chemistry, Pharmaceutical  
Drug Carriers  
Hydrogen-Ion Concentration  
Injections  
Liposomes  
Micelles  
Solubility  
Surface-Active Agents: PD, pharmacology

CN 0 (Drug Carriers); 0 (Liposomes); 0 (Micelles); 0 (Surface-Active Agents)

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

73.58

74.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-0.78

-0.78

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 13:13:29 ON 14 MAR 2007